ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Supernus Provides Regulatory Updates for SPN-812 and SPN-830 americanpharmaceuticalreview
November 20, 2020Supernus Pharmaceuticals announced regulatory updates for SPN-812 (viloxazine hydrochloride) for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age, and SPN-830 (apomorphine infusion pump) for ... -
Supernus Submits SPN-830 NDA for Apomorphine Infusion Pump americanpharmaceuticalreview
September 22, 2020Supernus Pharmaceuticals has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its apomorphine infusion pump (SPN-830) for the continuous treatment of ON-OFF episodes in adults with Parkinson’s disease (PD) ...
Pharma Sources Insight July 2025
